MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02664nam a2200253 a 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
vtls000045473 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
KUKTEM |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20251114204424.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100430t2010 my a f m 000 0 eng dd |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
THE0002288(Local) |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] |
|---|
| Level of rules in bibliographic description |
201905241221 |
| Level of effort used to assign nonsubject heading access points |
shamsul |
| Level of effort used to assign subject headings |
201108030915 |
| Level of effort used to assign classification |
Fida |
| Level of effort used to assign subject headings |
201107132316 |
| Level of effort used to assign classification |
VLOAD |
| Level of effort used to assign subject headings |
201004301112 |
| Level of effort used to assign classification |
ida |
| -- |
201004301056 |
| -- |
ida |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UMP |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
QR186.85 .I43 2009 rs Bc. |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Muhamad Nur Iman Ahmad Razali |
| 245 12 - TITLE STATEMENT |
|---|
| Title |
A simulation study on downstream processing of monoclonal antibodies production using superpro designer / |
| Statement of responsibility, etc. |
Muhamad Nur Iman Bin Ahmad Razali |
| 246 3# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
A simulation study on downstream processing of monoclonal antibodies production using superpro designer |
| Medium |
[computer file] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Kuantan, Pahang : |
| Name of publisher, distributor, etc. |
UMP, |
| Date of publication, distribution, etc. |
2009 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xiv, 53 p. : |
| Other physical details |
ill. (some col.) ; |
| Dimensions |
30 cm. + |
| Accompanying material |
1 computer disc |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Project paper (Bachelor of Chemical Engineering (Biotechnology)) -- Universiti Malaysia Pahang - 2009 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography : p. 51-52 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
The production of monoclonal antibodies and Fc fusion proteins form the largest and most rapidly expanding category of the biopharmaceuticals today with the annual sales exceeding USD$8 billion with the application across a wide range of diseases especially for the immunotherapy purpose. With the growth of this class of biomolecules, significant thought on the most efficient downstream processing steps for monoclonal antibodies has been taken into the highly consideration by the manufacturer in order to obtain the highest yield with the highest purity of the product which is why the simulation study are crucial in this development. The objectives of this study are to propose the most suitable framework of downstream processing for monoclonal antibodies production in order to achieve highest purities of mAbs and to stimulate the propose framework using SuperPro Designer® simulator. The process was initially done via the disk stack centrifuge and followed by microfiltration in order to harvest the protein. Three column of chromatography (Protein A affinity, anion exchange and hydrophobic interaction) were used to obtain the highest purity of the therapeutic. Viral inactivation also was employed to free the product from the endotoxins and pyrogens. The propose steps then, was introduced into the SuperPro Designer® simulator and the result obtained were 100% purity of IgG with 9.49345 g/L of concentration and 0.16687 kg/batch with 76.3% of recovery of the product. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Monoclonal antibodies |